Cargando…

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer

ALK rearrangement is called the ‘diamond mutation’ in non‐small cell lung cancer (NSCLC). Accurately identifying patients who are candidates for ALK inhibitors is a key step in making clinical treatment decisions. In this study, a total of 783 ALK rearrangement‐positive NSCLC cases were identified b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zizong, Han, Yushuai, Tao, Houquan, Xu, Mengxiang, Liu, Zhengchuang, Zhu, Jianhua, Li, Wei, Ma, Jie, Liu, Zhifang, Wang, Weiran, Ma, Tonghui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158786/ https://www.ncbi.nlm.nih.gov/pubmed/36423218 http://dx.doi.org/10.1002/1878-0261.13348

Ejemplares similares

Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study
por: Li, Yue, et al.
Publicado: (2022)

Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late‐onset cancers
por: Hao, Shaoyu, et al.
Publicado: (2023)

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy
por: Zhang, Ning-Ning, et al.
Publicado: (2014)

Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study
por: Zhou, Shengyu, et al.
Publicado: (2023)

PBRM1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma
por: He, Xujun, et al.
Publicado: (2022)

Cassis: detection of genomic rearrangement breakpoints
por: Baudet, Christian, et al.
Publicado: (2010)

Precise detection of rearrangement breakpoints in mammalian chromosomes
por: Lemaitre, Claire, et al.
Publicado: (2008)

Exact breakpoints of the In(1)w (m4) rearrangement
por: Solodovnikov, Alexander, et al.
Publicado: (2022)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

HOXB7 overexpression promotes cell proliferation and correlates with poor prognosis in gastric cancer patients by inducing expression of both AKT and MARKs
por: He, Xujun, et al.
Publicado: (2016)

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report
por: Yang, Hong, et al.
Publicado: (2022)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes
por: Yao, Y., et al.
Publicado: (2022)

Detection of recurrent rearrangement breakpoints from copy number data
por: Ritz , Anna, et al.
Publicado: (2011)

Detection of gene expression changes at chromosomal rearrangement breakpoints in evolution
por: Muñoz, Adriana, et al.
Publicado: (2012)

Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis
por: Boeva, Valentina, et al.
Publicado: (2013)

Low FAT4 expression is associated with a poor prognosis in gastric cancer patients
por: Jiang, Xiaoting, et al.
Publicado: (2017)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
por: Feng, Chunlai, et al.
Publicado: (2021)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Recurrence of Chromosome Rearrangements and Reuse of DNA Breakpoints in the Evolution of the Triticeae Genomes
por: Li, Wanlong, et al.
Publicado: (2016)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation
por: Si, Wenzhang, et al.
Publicado: (2019)

Characterization of Chromosomal Breakpoints in 12 Cases with 8p Rearrangements Defines a Continuum of Fragility of the Region
por: Redaelli, Serena, et al.
Publicado: (2022)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Detection of ALK rearrangements in lung cancer patients using a homebrew PCR assay
por: Yu, Hui, et al.
Publicado: (2016)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
por: Jiang, Jun, et al.
Publicado: (2022)

Sweyjawbu expression is a predictor of ALK rearrangement status in lymphoma
por: Xue, Kai, et al.
Publicado: (2016)

Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
por: Mattsson, Johanna S. M., et al.
Publicado: (2016)

Cystic brain metastases in ALK-rearranged non-small cell lung cancer
por: Marta, Guilherme Nader, et al.
Publicado: (2018)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
por: Zhao, Ruiying, et al.
Publicado: (2022)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
por: Zhou, Xiaoyun, et al.
Publicado: (2019)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

On the distribution of cycles and paths in multichromosomal breakpoint graphs and the expected value of rearrangement distance
por: Feijão, Pedro, et al.
Publicado: (2015)

Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer
por: Doshi, Shivang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ssaa6o7v6jsulk3u6sk69v4ovs